# Evofem Biosciences, Inc. (EVFM)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/evofem-biosciences-inc/ JSON: https://steadybase.io/company/evofem-biosciences-inc.json Checked Nov 10, 2026. Latest filing read: Aug 14, 2026.

## Company

- Legal name: Evofem Biosciences, Inc.
- Ticker: EVFM (OTC)
- SEC CIK: 0001618835
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: San Diego, CA
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company
- Website: evofem.com
- Investor relations: https://investor.evofem.com/overview/default.aspx
- LinkedIn: https://www.linkedin.com/company/evofem
- Next earnings date: Nov 14, 2026 (estimated from past 8-K timing)

## Key facts

- Revenue: $20.2M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 11, 2026). Source: https://www.sec.gov/Archives/edgar/data/1618835/000149315226009686/0001493152-26-009686-index.html
- Operating income: $3.4M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 11, 2026). Source: https://www.sec.gov/Archives/edgar/data/1618835/000149315226009686/0001493152-26-009686-index.html
- Net income: $391,000 for the fiscal year ended Dec 31, 2025 (10-K filed Mar 11, 2026). Source: https://www.sec.gov/Archives/edgar/data/1618835/000149315226009686/0001493152-26-009686-index.html
- SG&A: $17.1M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 11, 2026). Source: https://www.sec.gov/Archives/edgar/data/1618835/000149315226009686/0001493152-26-009686-index.html
- Employees: 29 as of Feb 28, 2026, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1618835/000149315226009686/form10-k.htm
- Shares outstanding: 132,530,081 as of Aug 12, 2026 (10-Q filed Aug 14, 2026). Source: https://www.sec.gov/Archives/edgar/data/1618835/000149315226038328/0001493152-26-038328-index.html
- Auditor: Bpm LLP, Sacramento, California, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1618835/000149315226009686/form10-k.htm

## Business

for the Gulf Cooperative Commission (GCC) and MENA, under which Pharma 1 is expected to launch PHEXX in the UAE in 2026.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1618835/000149315226009686/form10-k.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $20.2M | $3.4M | $391,000 | $17.1M |
| Dec 31, 2024 | $19.4M | -$7.7M | -$8.9M | $20.7M |
| Dec 31, 2023 | $18.2M | -$17.8M | $53.0M | $26.6M |
| Dec 31, 2022 | $16.8M | -$84.1M | -$76.7M | $71.5M |
| Dec 31, 2021 | $8.2M | -$166.8M | -$205.2M | $137.9M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/evofem-biosciences-inc.json

## Officers and directors

- Saundra Pelletier, Chief Executive Officer. Source: 10-K filed Mar 11, 2026, https://www.sec.gov/Archives/edgar/data/1618835/000149315226009686/form10-k.htm
- Ivy Zhang, Chief Financial Officer. LinkedIn: https://linkedin.com/in/ivy-zhang-940b78a1. Source: 10-K filed Mar 11, 2026, https://www.sec.gov/Archives/edgar/data/1618835/000149315226009686/form10-k.htm

## Recent 8-K events

- Oct 15, 2026: Item 1.01, Entry into a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1618835/000149315226047227/form8-k.htm
- Sep 23, 2026: Item 1.01, Entry into a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1618835/000149315226043919/form8-k.htm
- Jul 20, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1618835/000149315226033910/form8-k.htm
- Jul 14, 2026: Item 1.01, Entry into a material definitive agreement; Item 2.03, Creation of a direct financial obligation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1618835/000149315226033184/form8-k.htm
- May 18, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1618835/000149315226024095/form8-k.htm
- Apr 30, 2026: Item 1.01, Entry into a material definitive agreement; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1618835/000149315226020417/form8-k.htm
- Apr 16, 2026: Item 1.01, Entry into a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1618835/000149315226017082/form8-k.htm
- Mar 19, 2026: Item 1.02, Termination of a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1618835/000149315226011613/form8-k.htm
- Mar 11, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1618835/000149315226009689/form8-k.htm
- Jan 12, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1618835/000149315226001886/form8-k.htm

## What management said

- "Evofem continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream" Saundra Pelletier, CEO of Evofem (8-K filed May 18, 2026). Source: https://www.sec.gov/Archives/edgar/data/1618835/000149315226024095/ex99-1.htm

## Latest filings

- 8-K filed Oct 15, 2026: https://www.sec.gov/Archives/edgar/data/1618835/000149315226047227/form8-k.htm
- 10-K filed Mar 11, 2026: https://www.sec.gov/Archives/edgar/data/1618835/000149315226009686/form10-k.htm
- 10-Q filed Aug 14, 2026: https://www.sec.gov/Archives/edgar/data/1618835/000149315226038328/form10-q.htm
- DEF 14A filed Oct 29, 2025: https://www.sec.gov/Archives/edgar/data/1618835/000149315225020062/formdef14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/